Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin

Annals of Oncology

Volumn 11, Issue 6, 2000, Pages 757-760

  Kakolyris, S ^a   Kouroussis, C ^a   Kalbakis, K ^a   Mavroudis, D ^a   Souglakos, J ^a   Vardakis, N ^a   Kremos, S ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Cisplatin; CPT 11; NSCLC; Salvage treatment

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FATIGUE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0033745655     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008370905807     Document Type: Article

References (8)

1. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue
2. Enhanced antitumour efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against lung tumour xenografts
3. Effects of CPT-11 in combination with other anticancer agents in culture
4. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer
5. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
6. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies
7. Phase I study of CPT-11 in combination with CDDP in metastatic non-small-cell lung cancer
8. Randomized study of Taxotere versus best supportive care in non-small-cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy